International Pulmonary Fibrosis (IPF) Summit

The 9th IPF Summit offers a deep dive into the next generation of therapeutic development. With the efficacy benchmarks set by Nintedanib and Pirfenidone now over a decade old, and new readouts on the horizon, the field is primed for disruption. This year’s gathering of experts will explore the data, endpoints, biomarkers, and trial designs shaping clinical success today. We’ll tackle big questions including: What does disease modification really look like? Can we safely target TGFB? Are we finally ready to reverse fibrosis rather than just slow it down? Expect sessions featuring physician perspectives on treatment selection, strategies to demonstrate value and efficacy in a changing landscape, and fresh approaches in RNA therapies, antifibrotics, and regenerative medicine.